VivoSeq
Other

Telitacicept

0

Pipeline Programs↗

5

Active Trials↗

1

Companies Involved↗

Telitacicept is an early-stage landscape with 0 programs across 1 company. The most active players are Vor Biopharma.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vor Biopharma

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Unknown status2 · 22%
Active, not recruiting2 · 22%
Recruiting2 · 22%
Not yet recruiting1 · 11%
Completed1 · 11%
Terminated1 · 11%

Clinical Trials

Trial Activity

9 trials

A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects
Recruiting·RRemeGen Co., Ltd.·Phase 1·NCT06549959·248 enrolled
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Recruiting·VVor Biopharma·Phase 3·NCT07404865·250 enrolled
Telitacicept for PGNMID: A Single-Arm Study
Active, not recruiting·PPeking University First Hospital·Phase 2·NCT07111338·10 enrolled
Immune Cell Subsets in SLE Patients Treated with Telitacicept
Active, not recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT06677801·50 enrolled
Telitacicept for the Treatment of Refractory RA
Not yet recruiting·CChinese SLE Treatment And Research Group·Phase 4·NCT07008196·30 enrolled
Effect of Telitacicept on Antibody Titers in Primary APS Patients
Completed·RRuijin Hospital·Phase 2·NCT06315530·20 enrolled
Telitacicept in Primary APS Patients
Terminated·PPeking Union Medical College Hospital·Phase 2·NCT05078710·20 enrolled
Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients
Unknown status·—·Phase 4·NCT05666336·30 enrolled
Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE
Unknown status·QQilu Hospital of Shandong University·N/A·NCT05644210·80 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)